Skip to main content
    U

    Ultragenyx (RARE)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $15.90
    -0.18 (-1.12%)

    Market Cap: $1.64B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Ultragenyx (RARE) Financials: Revenue, Profit and Cash Flow

    Updated Nov 3, 2026. Financial statements from company filings, amounts in US dollars.

    Ultragenyx reported revenue of $673.00M for the fiscal year ended Dec 31, 2025, up 20.2% from the year before. That year, net income was -$575.00M with a net margin of -85.4%, operating cash flow was -$466.00M and free cash flow was -$472.00M. The quarter ended Sep 30, 2026 had revenue of $173.00M and net income of -$118.00M.

    Revenue and Margins

    The operating margin was -79.5% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $133.00K, a compound annual rate of 158.0%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$673.00M+20.2%83.8%-79.5%-85.4%
    Dec 2024$560.00M+29.0%86.3%-95.7%-101.6%
    Dec 2023$434.00M+19.5%89.6%-131.1%-139.9%
    Dec 2022$363.33M+3.4%92.2%-178.6%-194.7%
    Dec 2021$351.41M+29.7%95.4%-108.6%-129.2%
    Dec 2020$271.03M+161.3%97.7%-121.8%-68.8%
    Dec 2019$103.71M+101.4%91.3%-409.0%-388.3%
    Dec 2018$51.49M+1871.5%97.8%-721.2%-383.7%
    Dec 2017$2.61M+1863.9%100.0%-12593.5%-11567.3%
    Dec 2016$133.00KN/A100.0%-186471.4%-184867.7%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$673.00M$560.00M$434.00M$363.33M$351.41M$271.03M$103.71M$51.49M$2.61M$133.00K
    Cost of revenue$109.00M$77.00M$45.00M$28.32M$16.01M$6.13M$9.01M$1.15M$1.00K$0
    Gross profit$564.00M$483.00M$389.00M$335.01M$335.40M$264.90M$94.71M$50.35M$2.61M$133.00K
    Research and development$750.00M$698.00M$648.00M$705.79M$497.15M$412.08M$357.36M$294.00M$231.64M$183.20M
    Operating income-$535.00M-$536.00M-$569.00M-$648.92M-$381.74M-$330.12M-$424.17M-$371.37M-$328.94M-$248.01M
    Net income-$575.00M-$569.00M-$607.00M-$707.42M-$454.02M-$186.57M-$402.73M-$197.61M-$302.14M-$245.87M
    EBITDA-$503.00M-$518.00M-$557.00M-$629.57M-$363.58M-$316.40M-$422.63M-$189.74M-$314.88M-$241.36M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$173.00M$214.00M$136.00M$207.28M$160.00M$167.00M$139.00M$164.65M$139.49M$147.03M$108.83M$127.14M
    Gross profit$141.00M$180.00M$106.00M$177.93M$132.00M$144.00M$110.00M$147.48M$118.47M$125.75M$91.30M$115.30M
    Operating income-$110.00M-$75.00M-$169.00M-$113.28M-$171.00M-$108.00M-$143.00M-$122.31M-$131.99M-$116.36M-$165.35M-$121.84M
    Net income-$118.00M-$92.00M-$185.00M-$128.56M-$180.00M-$115.00M-$151.00M-$133.20M-$133.52M-$131.60M-$170.68M-$123.55M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $81.00M by $340.00M. Shareholder equity was negative, at -$80.00M, as total liabilities of $1.60B exceeded total assets of $1.53B.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$1.53B$1.50B$1.49B$1.55B$1.52B$1.76B$1.14B$719.56M$490.75M$540.63M
    Current assets$951.00M$817.00M$732.18M$883.90M$856.60M$1.30B$851.02M$522.37M$269.58M$401.69M
    Cash and equivalents$421.00M$174.00M$213.58M$132.94M$307.58M$713.53M$433.58M$113.43M$100.49M$161.12M
    Total liabilities$1.60B$1.24B$1.22B$1.19B$599.84M$605.18M$481.73M$110.65M$107.30M$66.65M
    Short-term debt$81.00M$10.30M$12.60M$11.78M$11.07M$8.98M$7.24MN/AN/AN/A
    Shareholder equity-$80.00M$255.00M$275.41M$352.49M$922.56M$1.15B$653.76M$608.91M$383.45M$473.97M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$1.19B$1.26B$1.30B$1.53B$1.19B$1.31B$1.31B$1.50B$1.54B$1.62B$1.31B$1.49B
    Total liabilities$1.56B$1.55B$1.52B$1.60B$1.17B$1.15B$1.16B$1.24B$1.18B$1.19B$1.17B$1.22B
    Cash and equivalents$150.00M$125.00M$175.00M$434.00M$202.51M$176.31M$127.06M$173.73M$150.62M$480.69M$112.25M$213.58M
    Shareholder equity-$376.00M-$291.00M-$236.00M-$80.00M$9.16M$151.29M$144.25M$255.30M$346.83M$432.42M$140.26M$275.41M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$466.00M-$414.00M-$475.00M-$380.46M-$338.69M-$132.22M-$345.38M-$290.57M-$253.84M-$160.97M
    Capital expenditures$6.00M$7.00M$44.00M$116.12M$73.09M$43.91M$24.83M$4.08M$2.79M$10.19M
    Free cash flow-$472.00M-$421.00M-$519.00M-$496.59M-$411.79M-$176.13M-$370.21M-$294.64M-$256.64M-$171.16M
    Investing cash flow$236.00M-$18.00M$168.00M-$291.65M-$195.37M-$179.12M-$13.04M-$33.33M$55.48M$91.12M
    Financing cash flow$478.00M$399.00M$388.00M$501.21M$118.55M$600.27M$679.31M$336.85M$136.27M$138.68M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$43.00M-$97.00M-$197.00M-$99.83M-$91.00M-$109.00M-$166.00M-$79.31M-$67.00M-$76.96M-$190.73M-$84.10M
    Capital expenditures$2.00M$1.00M$1.00M$938.00K$1.00M$3.00M$1.00M$163.00K$1.62M$2.01M$3.21M$1.33M
    Free cash flow-$45.00M-$98.00M-$198.00M-$100.77M-$92.00M-$112.00M-$167.00M-$79.48M-$68.61M-$78.97M-$193.94M-$85.43M
    Last 12 quarters

    Frequently Asked Questions About RARE

    What is Ultragenyx's annual revenue?

    Ultragenyx reported revenue of $673.00M for the fiscal year ended Dec 31, 2025.

    How fast is Ultragenyx's revenue growing?

    Revenue was up 20.2% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 22.8%.

    Is Ultragenyx profitable?

    No. Ultragenyx reported net income of -$575.00M for the fiscal year ended Dec 31, 2025, with a net margin of -85.4%.

    How much free cash flow does RARE generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$466.00M minus capital expenditures of $6.00M produced free cash flow of -$472.00M.

    How much debt does Ultragenyx have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $81.00M and cash and equivalents of $421.00M.